Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 1/20 | 0.33 |
| ▸ | TOP2A | P11388 | 4/20 | 0.32 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6311139 | 1.00 | DUT (0.33) | DUTTOP2AFKBP1A | |
| SCHEMBL14515531 | 1.00 | DUT (0.33) | DUTTOP2AFKBP1A | |
| SCHEMBL17500043 | 0.82 | — | — | |
| SCHEMBL11970909 | 0.80 | FKBP1A (0.31) | FKBP1A | |
| SCHEMBL24607433 | 0.80 | — | — | |
| SCHEMBL12632024 | 0.79 | FKBP1A (0.33) | DUTTOP2AFKBP1A | |
| SCHEMBL8062803 | 0.79 | FKBP1A (0.33) | DUTTOP2AFKBP1A | |
| SCHEMBL31645669 | 0.78 | EPHX2 (0.34) | FKBP1A | |
| SCHEMBL9147380 | 0.77 | FKBP1A (0.30) | FKBP1A | |
| SCHEMBL24921214 | 0.76 | FKBP1A (0.33) | FKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6977265-B2 | Piperidine CCR-3 receptor antagonists | ROCHE PALO ALTO LLC (US) | 2005-12-20 | — | — | US | disclosed |
| EP-1453825-A1 | N-UREIDO-PIPERIDINES AS ANTAGONISTS VIII FOR CCR-3 RECEPTOR | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-08 | — | — | EP | disclosed |
| US-20030229121-A1 | Piperidine CCR-3 receptor antagonists | SYNTEX (U.S.A.) LLC | 2003-12-11 | — | — | US | disclosed |
| WO-2003045937-A1 | N-UREIDO-PIPERIDINES AS ANTAGONISTS VIII FOR CCR-3 RECEPTOR | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229121-A1 | Piperidine CCR-3 receptor antagonists | CCR1, CCR3, CCRL2 | DUT 1852/4885TOP2A 2897/4885FKBP1A 3656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.